Prodrug kit for multi-pronged chemotherapy
Summary
The European Patent Office published patent application EP4551565A1 for a prodrug kit designed for multi-pronged chemotherapy, filed by Alex Zounek. The invention covers pharmaceutical compositions including heterocyclic compounds classified under C07D and A61K, with applications in cancer treatment (A61P 35/00). The patent designates all current EPO member states.
What changed
EPO published international patent application EP4551565A1 for a prodrug kit used in multi-pronged chemotherapy. The invention relates to heterocyclic compounds (C07D 311/12, 401/14, 403/04, 405/14, 471/04, 519/04) combined with pharmaceutical excipients (A61K 47/55, 47/64), targeting cancer treatment (A61P 35/00). The applicant, Zounek Alex, seeks protection across 35 EPO designated contracting states including Germany, France, the UK, Italy, Spain, and other EU/EEA nations.
Pharmaceutical companies developing prodrug-based cancer therapeutics should review the patent claims to assess potential freedom-to-operate implications or licensing opportunities. The patent publication establishes priority dates and defines the scope of claims that may eventually be granted. Companies with overlapping research programs should consider invalidity analysis or proactive licensing negotiations before commercializing similar products in designated territories.
What to do next
- Review patent claims for freedom-to-operate analysis if developing competing prodrug chemotherapy products
- Assess licensing requirements for products falling within the designated territories
- Monitor the patent prosecution timeline for potential oppositions after grant
Archived snapshot
Apr 2, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
PRODRUG KIT FOR MULTI-PRONGED CHEMOTHERAPY
Publication EP4551565A1 Kind: A1 Mar 25, 2026
Applicants
Zounek, Alex
Inventors
Zounek, Alex
IPC Classifications
C07D 311/12 20060101AFI20240112BHEP C07D 401/14 20060101ALI20240112BHEP C07D 403/04 20060101ALI20240112BHEP C07D 405/14 20060101ALI20240112BHEP C07D 471/04 20060101ALI20240112BHEP C07D 519/04 20060101ALI20240112BHEP A61K 47/55 20170101ALI20240112BHEP A61P 35/00 20060101ALI20240112BHEP A61K 47/64 20170101ALI20240112BHEP
Designated States
AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR
Named provisions
Related changes
Get daily alerts for ChangeBridge: EPO Bulletin - Organic Chemistry (C07D)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from EPO.
The plain-English summary, classification, and "what to do next" steps are AI-generated from the original text. Cite the source document, not the AI analysis.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ChangeBridge: EPO Bulletin - Organic Chemistry (C07D) publishes new changes.